O
BMY icon

OrbiMed’s Bristol-Myers Squibb BMY Stock Holding History

OrbiMed’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-200,000
Closed -$10.9M – 141
2017
Q1 		$10.9M Buy
+200,000
New +$11M 0.12% 93

Other funds holding BMY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

OrbiMed's BMY Position: Q1 2026 in Review

OrbiMed increased its Bristol-Myers Squibb (BMY) stake by 19% in Q1 2026, buying an estimated $8.74M and bringing the position to 925,000 shares worth $56.1M. The position accounts for 1.11% of the portfolio, ranked #25.

OrbiMed first reported a position in BMY in Q2 2013 and has held it in 42 quarters since. The position peaked at $577M in Q4 2015. 2,521 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • OrbiMed held 925,000 shares of Bristol-Myers Squibb worth $56.1M as of Q1 2026.
  • OrbiMed bought 150,000 Bristol-Myers Squibb shares in Q1 2026, an estimated $8.74M.
  • Bristol-Myers Squibb made up 1.11% of OrbiMed's portfolio in Q1 2026, its #25 holding.
  • OrbiMed first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 42 quarters since.
  • OrbiMed's Bristol-Myers Squibb position peaked at $577M in Q4 2015.
  • 2,521 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.